Objective: This study described the prevalence of and correlates of depression and anxiety in adult patients with hemophilia A and B. Methods: In this cross-sectional study, we investigated patients with hemophilia who were being seen at an adult hemophilia center in Turkey. Participants were screened for depression and anxiety during their annual clinic visit, which included administration of the Beck Depression Inventory and State-Trait Anxiety Scale. Results: Of the 90 patients, 22 (24.4%) met criteria for significant depressive symptoms and 67 (74.4%) met criteria for significant anxiety symptoms. There were no significant associations between depression and any psychosocial or clinical characteristics or adherence to hemophilia prophylaxis, except for educational status. No association was found between state and trait anxiety scores and psychosocial and clinical characteristics other than hemophilia type. After adjusting for confounding factors, multivariable analysis showed that high school education level was associated with depression (OR: 1.87, CI: 1.31–2.36, P = .010) and type B hemophilia was associated with anxiety (OR: 1.32, CI: 1.09–1.75, P = .042). Conclusion: Depression and anxiety are major psychiatric comorbidities in patients with hemophilia in Turkey. Routine evaluation for mood and anxiety disorders are important in the routine care of patients with haemophilia.

The demand for Janus Kinase-2 (JAK2) testing has been disproportionate to the low yield of positive results, which highlights the need for more discerning test strategies. The aim of this study is to introduce an artificial intelligence application as a more rational approach for testing JAK2 mutations in cases of erythrocytosis. Test results were sourced from samples sent to a tertiary hospital’s genetic laboratory between 2017 and 2023, meeting 2016 World Health Organization criteria for JAK2V617F mutation testing. The JAK2 Somatic Mutation Screening Kit was used for genetic testing. Machine learning models were trained and tested using Python programming language. Out of 458 cases, JAK2V617F mutation was identified in 13.3%. There were significant differences in complete blood count parameters between mutation carriers and non-carriers. Various models were trained with data, with the random forest (RF) model demonstrating superior precision, recall, F1-score, accuracy, and area under the receiver operating characteristic, all reaching 100%. Gradient boosting (GB) model also showed high scores. When compared with existing algorithms, the RF and GB models displayed superior performance. The RF and GB models outperformed other methods in accurately identifying and classifying erythrocytosis cases, offering potential reductions in unnecessary testing and costs.

Cancer-related anemia (CRA) is a common complication during and after cancer treatment. It contributes to impaired functional capacity, reduced quality of life (QoL), and worse prognosis Iron deficiency (ID) is a frequent underlying cause; therefore, intravenous iron replacement may improve both hematologic and patient-centered outcomes. However, prospective data on QoL and functional status in CRA remain limited. We prospectively evaluated the effects of ferric carboxymaltose (FCM) on QoL and cardiorespiratory fitness in cancer patients with ID. A prospective observational study was conducted between March and October 2023 with patients suffering from ID and undergoing FCM iron supplementation. The study involved QoL measurement through the SF-36 questionnaire and cardiorespiratory fitness assessment using the six-minute walk test (6MWT). Primary endpoints were physical functioning and vitality (energy/fatigue) subscales of SF-36. Secondary endpoints were six-minute walking distance and other subscales of SF-36. Data analysis was performed using various statistical tests, with a post-hoc power analysis showed sufficient (> 99%) power for primary endpoints. Thirty patients were enrolled, most commonly with colon (40%) and breast cancer (20%); 70% had ECOG 1 status. FCM led to significant improvements in hemoglobin and iron indices. While 6MWT distance showed a non-significant upward trend, SF-36 scores improved significantly in physical functioning, vitality, and emotional well-being, underscoring a multidimensional benefit on QoL. Intravenous iron replacement in cancer patients with ID improves hematologic parameters and confers meaningful gains in physical functioning, vitality, and emotional health. These findings support systematic iron assessment and supplementation as part of supportive oncology care.

Objectives: This study aimed to compare surgical outcomes between patients scheduled for cardiovascular surgery diagnosed with anemia according to the World Health Organization criteria who received intravenous iron replacement and those who were not anemic. Patients and methods: This retrospective study analyzed patients who underwent cardiovascular surgery between February 2021 and January 2024. Patients with preoperative anemia treated with intravenous iron replacement were compared with nonanemic patients. Data on demographics, preoperative conditions, surgical details, and postoperative outcomes were analyzed. Results: Of the 193 patients (142 males, 51 females; mean age: 62±10 years; range, 27 to 82 years) analyzed, 173 survived, and 20 did not. Surviving patients were younger and had a lower body mass index. Comorbidities such as congestive heart failure and a history of cerebrovascular events were associated with mortality. Laboratory results showed significant differences in hemoglobin levels and iron binding capacity between survivors and nonsurvivors. The study found no significant differences in surgical procedures or reoperation rates between the groups. However, nonsurvivors had more postoperative complications. Multivariate analysis identified cardiopulmonary bypass time and new-onset acute renal failure as independent risk factors for 30-day mortality. Anemic patients treated with intravenous iron replacement had comparable perioperative outcomes to nonanemic patients, including similar lengths of intensive care unit and hospital stays and mortality rates. Conclusion: Treatment of preoperative anemia with intravenous iron replacement in patients undergoing cardiovascular surgery resulted in outcomes comparable to those of nonanemic patients. This suggests that short-term intravenous iron replacement may be an effective strategy to improve surgical readiness and outcomes in anemic patients.